сгенерировать QR код
Открытый доступ
Только для подписчиков
Самостоятельное тестирование на вирус папилломы человека как скрининговый метод выявления групп риска
https://doi.org/10.30629/0023-2149-2024-102-5-6-415-421
Аннотация
В связи с высокой распространенностью рака шейки матки необходимо проведение мероприятий, направленных на уменьшение его частоты за счет вакцинации, проведения скрининга, выявления и лечения предраковых состояний. В статье представлен системный анализ научных данных использования тестирования для самостоятельного отбора проб на вирус папилломы человека как инструмента повышения эффективности скрининга и выявления предраковых заболеваний шейки матки. Показано, что использование подобных тестов, которые основаны на полимеразной цепной реакции, имеют схожую клиническую точность по сравнению с забором материала врачом. Таким образом, данный вариант является перспективным способом расширения охвата скринингом на рак шейки матки за счет тестирования пациенток, не проходивших обследование. Наличие предполагаемой экономической эффективности также предопределяет актуальность и перспективность данных тестов. Однако необходимо проведение дальнейших исследований, направленных на оценку внедрения данной стратегии в рутинную практику.
Об авторах
Т. А. Громова
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава России (Сеченовский Университет)
Россия
Россия
Громова Татьяна Александровна — канд. мед. наук., ассистент кафедры акушерства и гинекологии ИКМ им. Н.В. Склифосовского
Москва
С. А. Леваков
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава России (Сеченовский Университет)
Россия
Россия
Леваков Сергей Александрович — д-р мед. наук, профессор, заведующий кафедрой акушерства и гинекологии ИКМ им. Н.В. Склифосовского
Москва
Д. Р. Мушкюрова
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава России (Сеченовский Университет)
Россия
Россия
Мушкюрова Диана Рамазановна — аспирант кафедры акушерства и гинекологии ИКМ им. Н.В. Склифосовского
Москва
Список литературы
1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global cancer statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. DOI: 10.3322/caac.21660
2. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. DOI: 10.3322/caac.21492
3. Female Genital Tumours. WHO Classification of Tumors. 5th ed. Volume 4 WHO Press; Geneva, Switzerland. 2020.
4. Ferlay J., Colombet M., Soerjomataram I., Parkin D.M., Piñeros M., Znaor A., Bray F. Cancer statistics for the year 2020: An overview. Int. J. Cancer. 2021;149:778–789. DOI: 10.1002/ijc.33588
5. Brisson M., Drolet M. Global elimination of cervical cancer as a public health problem. Lancet Oncol. 2019;20:319–21. DOI: 10.1016/S1470-2045(19)30072-5
6. Canfell K., Kim J.J., Brisson M., Keane A., Simms K.T., Caruana M. et al. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020; 395(10224):591–603. DOI: 10.1016/S0140-6736(20)30157-4
7. Brisson M., Kim J.J., Canfell K., Drolet M., Gingras G., Burger E.A. et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395(10224):575–590. DOI: 10.1016/S0140-6736(20)30068-4
8. WHO Goal 3: Ensure healthy lives and promote well-being for all at all ages. Target 3.4: by 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being. Indicator 3.4.1: mortality rate attributed to cardiovascular disease, cancer, diabetes or chronic respiratory disease. 2017. [Electronic resource]. URL: https://unstats.un.org/sdgs/metadata/files/Metadata-03-04-01.pdf
9. World Health Organization. Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem. WHO. 2021. [Electronic resource]. URL: https://www.who.int/publications/i/item/9789240014107
10. Zhang Q., Xie W., Wang F., Li R.H., Cui L., Wang H., Fu X., Song J. Epidemiological Investigation and Risk Factors for Cervical Lesions: Cervical Cancer Screening Among Women in Rural Areas of Henan Province China. Med. Sci. Monit. 2016;22:1858–1865. DOI: 10.12659/MSM.894663
11. American Cancer Society. The American Cancer Society Guidelines for the Prevention and Early Detection of Cervical Cancer. 2022. [Electronic resource]. URL: https://www.cancer.org/cancer/cervical-cancer/detection-diagnosis-staging/cervical-cancer-screening-guidelines.html
12. Yeo-Teh N.S.L., Ito Y., Jha S. High-Risk Human Papillomaviral Oncogenes E6 and E7 Target Key Cellular Pathways to Achieve Oncogenesis. Int. J. Mol. Sci. 2018;19:1706. DOI: 10.3390/ijms19061706
13. Volkova L.V., Pashov A.I., Omelchuk N.N. Cervical carcinoma: oncobiology and biomarkers. Int. J. Mol. Sci. 2021; 22(22):12571. (In Russian)]. DOI: 10.3390/ijms222212571
14. IARC Working Group. Human Papillomaviruses: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. International Agency for Research on Cancer. Accessed May 2, 2021. [Electronic resource]. URL: https://monographs.iarc.who.int/wp‐content/uploads/2018/06/mono90.pdf
15. Клинические рекомендации. Цервикальная интраэпителиальная неоплазия, эрозия и эктропион шейки матки. 2022; Министерство здравоохранения Российской Федерации.
16. Piña-Sánchez P. Human Papillomavirus: Challenges and Opportunities for the Control of Cervical Cancer. Arch. Med. Res. 2022;53(8):753–769. DOI: 10.1016/j.arcmed.2022.11.009
17. Markowitz L.E., Schiller J.T. Human Papillomavirus Vaccines. J. Infect. Dis. 2021; 224(12):367–S378. DOI: 10.1093/infdis/jiaa621
18. de Martel C., Plummer M., Vignat J., Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int. J. Cancer. 2017;141(4):664–670. DOI: 10.1002/ijc.30716
19. Beachler D.C., Kreimer A.R., Schiffman M., Herrero R., Wacholder S., Rodriguez A.C. et al. Costa Rica HPV Vaccine Trial (CVT) Group. Multisite HPV16/18 vaccine efficacy against cervical, anal, and oral HPV infection. J. Natl. Cancer Inst. 2015;108(1):djv302. DOI: 10.1093/jnci/djv302
20. Bruni L., Albero G., Serrano B., Mena M., Collado J.J., Gómez D. et al. ICO/IARC Information centre on HPV and cancer (HPV Information Centre). Human papillomavirus and related diseases in the world. 2023. [Electronic resource]. URL: https://hpvcentre.net/statistics/reports/XWX.pdf
21. Alarcón-Romero L.D.C., Organista-Nava J., Gómez-Gómez Y., Ortiz-Ortiz J., Hernández-Sotelo D., Del Moral-Hernández O. et al. Prevalence and distribution of human papillomavirus genotypes (1997-2019) and their association with cervical cancer and precursor lesions in women from Southern Mexico. Cancer Control. 2022;29:10732748221103331. DOI: 10.1177/10732748221103331
22. Shen-Gunther J., Xia Q., Cai H., Wang Y. HPV DeepSeq: An ultra-fast method of NGS Data analysis and visualization using automated workflows and a customized papillomavirus database in CLC genomics workbench. Pathogens. 2021;10(8):1026. DOI: 10.3390/pathogens10081026
23. Vargas-Robles D., Magris M., Morales N., de Koning M.N.C., Rodríguez I., Nieves T. et al. . High rate of infection by only oncogenic human papillomavirus in amerindians. mSphere. 2018;3(3):e00176– 18. DOI: 10.1128/mSphere.00176-18
24. Basukala O., Banks L. The Not-So-Good, the Bad and the Ugly: HPV E5, E6 and E7 Oncoproteins in the Orchestration of Carcinogenesis. Viruses. 2021;13(10):1892. DOI: 10.3390/v13101892
25. Liu M., Han Z., Zhi Y., Ruan Y., Cao G., Wang G. et al. Long-read sequencing reveals oncogenic mechanism of HPV-human fusion transcripts in cervical cancer. Transl. Res. 2023;253:80–94. DOI: 10.1016/j.trsl.2022.09.004
26. Zhang R., Shen C., Zhao L., Wang J., McCrae M., Chen X., Lu F. Dysregulation of host cellular genes targeted by human papillomavirus (HPV) integration contributes to HPV-related cervical carcinogenesis. Int. J. Cancer. 2016;138(5):1163–74. DOI: 10.1002/ijc.29872
27. Xu B., Chotewutmontri S., Wolf S., Klos U., Schmitz M., Dürst M., Schwarz E. Multiplex identification of human papillomavirus 16 DNA integration sites in cervical carcinomas. PLoS One. 2013;8(6):e66693. DOI: 10.1371/journal.pone.006669
28. de Miguel F.J., Sharma R.D., Pajares M.J., Montuenga L.M., Rubio A., Pio R. Identification of alternative splicing events regulated by the oncogenic factor SRSF1 in lung cancer. Cancer Res. 2014;74(4):1105–15. DOI: 10.1158/0008-5472.CAN-13-1481
29. Sudenga S.L., Shrestha S. Key considerations and current perspectives of epidemiological studies on human papillomavirus persistence, the intermediate phenotype to cervical cancer. Int. J. Infect Dis. 2013;17(4):e216–20. DOI: 10.1016/j.ijid.2012.12.027
30. Vats A., Trejo-Cerro O., Thomas M., Banks L. Human papillomavirus E6 and E7: What remains? Tumour Virus Res. 2021;11:200213. DOI: 10.1016/j.tvr.2021.200213
31. Lei J., Ploner A., Lagheden C., Eklund C., Nordqvist Kleppe S., Andrae B., Elfström K.M., Dillner J., Sparén P., Sundström K. High-risk human papillomavirus status and prognosis in invasive cervical cancer: a nationwide cohort study. PLoS Med. 2018;15:e1002666. DOI: 10.1371/journal.pmed.1002666
32. Balasubramaniam S.D., Balakrishnan V., Oon C.E., Kaur G. Key molecular events in cervical cancer development. Medicina (Kaunas). 2019;55(7):384. DOI: 10.3390/medicina55070384
33. Rahangdale L., Mungo C., O’Connor S., Chibwesha C.J., Brewer N.T. Human papillomavirus vaccination and cervical cancer risk. BMJ. 2022;379:e070115. DOI: 10.1136/bmj-2022-070115
34. Demarco M., Hyun N., Carter-Pokras O., Raine-Bennett T.R., Cheung L., Chen X. et al. A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs. EClinicalMedicine. 2020;22:100293. DOI: 10.1016/j.eclinm.2020
35. Basu P., Malvi S.G., Joshi S., Bhatla N., Muwonge R., Lucas E.et al. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. Lancet Oncol. 2021;22(11):1518–1529. DOI: 10.1016/S1470-2045(21)00453-8
36. FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old FDA. 2018. [Electronic resource]. URL: https://www.fda.gov/news-events/press-announcements/fda-approves-expanded-use-gardasil-9-include-individuals-27-through-45-years-old
37. American College of Obstetricians and Gynecologist. Updated Cervical Cancer Screening Guidelines. 2022. [Electronic resource]. URL: https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2021/04/updated-cervical-cancer-screening-guidelines
38. United Kingdom National Screening Committee Guidance. Cervical Screening: Programme Overview. 2022. [Electronic resource]. URL: https://www.gov.uk/guidance/cervical-screening-programme-overview
39. National Cancer Institute Cervical Cancer Screening (PDQ®) - Health Professional Version. 2022. [Electronic resource]. URL: https://www.cancer.gov/types/cervical/hp/cervical-screening-pdq
40. Hong Kong Centre for Health Protection & Cancer Expert Working Group on Cancer Prevention and Screening Recommendations on Prevention and Screening for Cervical Cancer for Health Professionals. 2022. [Electronic resource]. URL: https://www.chp.gov.hk/en/recommendations/34/index.html
41. United States Preventive Services Task Force Screening for Cervical Cancer US Preventive Services Task Force Recommendation Statement. 2022. [Electronic resource]. URL: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/cervical-cancer-screening
42. Sawaya G.F., Kulasingam S., Denberg T.D., Qaseem A. Clinical guidelines committee of american college of physicians cervical cancer screening in average-risk women: best practice advice from the clinical guidelines committee of the american college of physicians. Ann. Intern. Med. 2015;162:851–859. DOI: 10.7326/M14-2426
43. Cancer council australia national cervical screening program: guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding. 2022. [Electronic resource]. URL: https://www.cancer.org.au/clinical-guidelines/cervical-cancer-screening/summary-of-recommendations
44. The royal australian college of general practitioners early detection of cancers. Cervical cancer. 2022. [Electronic resource]. URL: https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgpguidelines/view-all-racgp-guidelines/guidelines-for-preventive-activities-in-general-pr/early-detection-of-cancers/cervical-cancer
45. Canadian task force on preventive health care recommendations on screening for cervical cancer. 2022. [Electronic resource]. URL: https://www.cmaj.ca/content/185/1/35.full
46. The royal australian college of general practitioners early detection of cancers. Cervical cancer. 2022. (accessed on 8 August 2022). [Electronic resource]. URL: https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgpguidelines/guidelines-for-preventive-activities-in-general-pr/early-detection-of-cancers/cervical-cancer
47. Polman N.J., Snijders P.J.F., Kenter G.G., Berkhof J., Meijer C.J.L.M. HPV-based cervical screening: Rationale, expectations and future perspectives of the new Dutch screening programme. Prev. Med. 2019;119:108–117. DOI: 10.1016/j.ypmed.2018.12.021
48. Zhang Q., Xie W., Wang F., Li R.H., Cui L., Wang H., Fu X., Song J. Epidemiological Investigation and Risk Factors for Cervical Lesions: Cervical Cancer Screening Among Women in Rural Areas of Henan Province China. Med. Sci. Monit. 2016;22:1858–65. DOI: 10.12659/msm.894663
49. Sravani A.B., Ghate V,. Lewis S. Human papillomavirus infection, cervical cancer and the less explored role of trace elements. Biol. Trace Elem. Res. 2023; 201(3):1026–1050. DOI: 10.1007/s12011-022-03226-2
50. US Food and drug administration (FDA) executive summary: new approaches in the evaluation for high-risk human papillomavirus nucleic acid detection devices. 2020. [Electronic resource]. URL: https://www.fda.gov/media/122799/download
51. US Preventive Services Task Force; Curry S.J., Krist A.H., Owens D.K., Barry M.J., Caughey A.B., Davidson K.W. et al. Screening for cervical cancer: US preventive services task force recommendation statement. JAMA. 2018;320(7):674–686. DOI: 10.1001/jama.2018.10897
52. Salazar K.L., Duhon D.J., Olsen R., Thrall M. A review of the FDA-approved molecular testing platforms for human papillomavirus. J. Am. Soc. Cytopathol. 2019; 8: 284–292. DOI: 10.1016/j.jasc.2019.06.001
53. Bhatla N., Singhal S. Primary HPV screening for cervical cancer. Best Pract. Res. Clin. Obstet. Gynaecol. 2020;65:98–108. DOI: 10.1016/j.bpobgyn.2020.02.008
54. Kyrgiou M., Arbyn M., Bergeron C., Bosch F.X., Dillner J., Jit M. et al. Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC). Br. J. Cancer. 2020;123(4):510–517. DOI: 10.1038/s41416-020-0920-9
55. Verdoodt F., Jentschke M., Hillemanns P., Racey C.S., Snijders P.J.F., Arbyn M. Reaching women who do not participate in the regular cervical cancer screening programme by offering self-sampling kits: a systematic review and meta-analysis of randomised trials. Eur. J. Cancer. 2015;51:2375–2385. DOI: 10.1016/j.ejca.2015.07.006
56. Arbyn M., Gultekin M., Morice P., Nieminen P., Cruickshank M., Poortmans P. et al. The European response to the WHO call to eliminate cervical cancer as a public health problem. Int. J. Cancer. 2021;148(2):277–284. DOI: 10.1002/ijc.33189
57. Pouliakis A., Valasoulis G., Michail G., Salamalekis E., Margari N., Kottaridi C. et al. New Aspects and an artificial intelligence approach for the detection of cervical abnormalities: The COVID-19 Pandemic Era. In: Anastasius M., editor. Quality of Healthcare in the Aftermath of the COVID-19 Pandemic. IGI Global; Hershey, PA, USA: 2022:192–214. DOI: 10.4018/978-1-7998-9198-7.ch011
58. Elfström K.M., Dillner J. Cervical cancer screening improvements with self-sampling during the COVID-19 pandemic. medRxiv. 2022;2022:22277806. DOI: 10.1101/2022.07.19.22277806
59. European Commission European Guidelines for Quality Assurance in Cervical Cancer Screening. 2nd ed.: Supplements. 2022. [Electronic resource]. URL: https://op.europa.eu/pl/publication-detail/-/publication/a41a4c40-0626-4556-af5b-2619dd1d5ddc
60. Woo Y.L., Khoo S.P., Gravitt P., Hawkes D., Rajasuriar R., Saville M. The Implementation of a primary HPV self-testing cervical screening program in malaysia through program ROSE-lessons learnt and moving forward. Curr. Oncol. 2022;29:7379–7387. DOI: 10.3390/curroncol29100579
61. World Health Organization. Regional Committee for Europe. Roadmap to accelerate the elimination of cervical cancer as a public health problem in the WHO European Region 2022–2030. Draft for the Seventy-second Regional Committee for Europe Background document. 2022. [Electronic resource]. URL: https://iris.who.int/bitstream/handle/10665/362396/72bg17e-Roadmap-CervicalCancer.pdf?sequence=1&isAllowed=y
62. Auvinen E., Nieminen P., Pellinen J., Dillner J., Tarkkanen J., Virtanen A. Human papillomavirus self-sampling with mRNA testing benefits routine screening. Int. J. Cancer. 2022;151(11):1989–1996. DOI: 10.1002/ijc.34170
63. Yeh P.T., Kennedy C.E., De Vuyst H., Narasimhan M. Self-sampling for human papillomavirus (HPV) testing: a systematic review and meta-analysis. BMJ Glob. Health. 2019;4:e001351. DOI: 10.1136/bmjgh-2018-001351
64. Harding-Esch E.M., Hollis E., Mohammed H., Saunders J.M. Self-sampling and self-testing for STIs and HIV: the case for consistent nomenclature. Sex Transm. Infect. 2017;93(2):445–448. DOI: 10.1136/sextrans-2016-052841
65. Fargnoli V., Petignat P., Burton-Jeangros C. To what extent will women accept HPV self-sampling for cervical cancer screening? A qualitative study conducted in Switzerland. Int. J. Womens Health. 2015;7:883–8. DOI: 10.2147/IJWH.S90772
66. Arbyn M., Smith S.B., Temin S., Sultana F., Castle P. Collaboration on Self-Sampling and HPV Testing. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analysis. BMJ. 2018;363:k4823. DOI: 10.1136/bmj.k4823
67. Hawkes D., Keung M.H.T,. Huang Y., McDermott T.L., Romano J., Saville M., Brotherton J.M.L. Self-collection for cervical screening programs: from research to reality. Cancers (Basel). 2020;12(4):1053. DOI: 10.3390/cancers12041053
68. Arbyn M., Verdoodt F., Snijders P.J., Verhoef V.M., Suonio E., Dillner L. et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol. 2014;15(2):172–83. DOI: 10.1016/S1470-2045(13)70570-9
69. Reiter P., Richardson M. Acceptability of human papillomavirus selftest devices among women from high-risk populations. J. Womens Health Issues Care. 2016;5(1). DOI: 10.4172/2325-9795.1000216
70. Polman N.J., Ebisch R.M.F., Heideman D.A.M., Melchers W.J.G., Bekkers R.L.M., Molijn A.C. et al. Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial. Lancet Oncol. 2019;20(2):229–238. DOI: 10.1016/S1470-2045(18)30763-0
71. Arbyn M., Castle P.E. Offering self-sampling kits for HPV testing to reach women who do not attend in the regular cervical cancer screening program. Cancer Epidemiol Biomarkers Prev. 2015;24(5):769– 72. DOI: 10.1158/1055-9965.EPI-14-1417
72. Madzima T.R., Vahabi M., Lofters A. Emerging role of HPV self-sampling in cervical cancer screening for hard-to-reach women: Focused literature review. Can Fam Physician. 2017;63(8):597–601. [Electronic resource]. URL: https://pubmed.ncbi.nlm.nih.gov/28807952/
73. Lozar T., Nagvekar R., Rohrer C., Dube Mandishora R.S., Ivanus U., Fitzpatrick M.B.. Cervical cancer screening postpandemic: self-sampling opportunities to accelerate the elimination of cervical cancer. Int. J. Womens Health. 2021;13:841–859. DOI: 10.2147/IJWH.S288376
74. Bosgraaf R.P., Verhoef V.M., Massuger L.F., Siebers A.G., Bulten J., de Kuyper-de Ridder G.M. et al. Comparative performance of novel self-sampling methods in detecting high-risk human papillomavirus in 30,130 women not attending cervical screening. Int. J. Cancer. 2015;136(3):646–55. DOI: 10.1002/ijc.29026
75. Di Gennaro G., Licata F., Trovato A., Bianco A. Does self-sampling for human papilloma virus testing have the potential to increase cervical cancer screening? An updated meta-analysis of observational studies and randomized clinical trials. Front. Public Health. 2022;10:1003461. DOI: 10.3389/fpubh.2022.1003461
76. Van Keer S., Peeters E., Vanden Broeck D., De Sutter P., Donders G., Doyen J. et al. Clinical and analytical evaluation of the RealTime High Risk HPV assay in Colli-Pee collected first-void urine using the VALHUDES protocol. Gynecol. Oncol. 2021;162(3):575–583. DOI: 10.1016/j.ygyno.2021.06.010
77. Lefeuvre C., Pivert A., Guillou-Guillemette H.L., Lunel-Fabiani F., Veillon P., Le Duc-Banaszuk A.S., Ducancelle A. Urinary HPV DNA testing as a tool for cervical cancer screening in women who are reluctant to have a Pap smear in France. J. Infect. 2020;81(2):248–254. DOI: 10.1016/j.jinf.2020.05.006
78. Colli-Pee: An innovative solution for non-invasive urine collection and stabilization. Novosanis. 2021. [Electronic resource]. URL: https://novosanis.com/our-products
79. Li J., Wu R., Qu X., Huang X., Li L., Lin Z. et al. Effectiveness and feasibility of self-sampling for human papillomavirus testing for internet-based cervical cancer screening. Front Public Health. 2022;10:938272. DOI: 10.3389/fpubh.2022.938272
80. Smith M.A., Hall M.T., Saville M., Brotherton J.M.L., Simms K.T., Lew J.B. et al. Could HPV Testing on Self-collected Samples Be Routinely Used in an Organized Cervical Screening Program? A Modeled Analysis. Cancer Epidemiol Biomarkers Prev. 2021;30(2):268–277. DOI: 10.1158/1055-9965
Рецензия
Для цитирования:
Громова Т.А., Леваков С.А., Мушкюрова Д.Р. Самостоятельное тестирование на вирус папилломы человека как скрининговый метод выявления групп риска. Клиническая медицина. 2024;102(5-6):415-421. https://doi.org/10.30629/0023-2149-2024-102-5-6-415-421
For citation:
Gromova T.A., Levakov S.A., Mushkyurova D.R. Self-testing for human papillomavirus as a screening method for identifying risk groups. Clinical Medicine (Russian Journal). 2024;102(5-6):415-421. (In Russ.) https://doi.org/10.30629/0023-2149-2024-102-5-6-415-421
Просмотров:
147
Послать статью по эл. почте 